MarketCap
Facebook
X
TelegramQuarterly report 2022-Q4
added 02-09-2023
Meridian Bioscience Operating Expenses 2011-2026 | VIVO
Annual Operating Expenses Meridian Bioscience
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 134 M | 108 M | 94.9 M | 81 M | 85.8 M | 80.8 M | 74.3 M | 65.8 M | 64.9 M | 63.7 M | 60.6 M | 59.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 134 M | 59.3 M | 81.1 M |
Quarterly Operating Expenses Meridian Bioscience
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 59.6 M | - | - | 32.3 M | 28.9 M | - | 21.4 M | 23.6 M | 26.9 M | 66.3 M | 21.3 M | 26.9 M | 22.3 M | 62.3 M | 21.8 M | 22 M | 21 M | 74.1 M | 23.2 M | 21 M | 23.9 M | 65.1 M | 26.8 M | 23.7 M | 19 M | 55.6 M | 19.2 M | 19.4 M | 18 M | 49.3 M | 15.9 M | 18 M | 16.6 M | 48.4 M | 16.1 M | 16.6 M | 16.4 M | 46.1 M | 14.9 M | 16.4 M | 15.7 M | 44.3 M | 14.8 M | 15.7 M | 14.7 M | 44.6 M | 15.2 M | 14.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 74.1 M | 14.7 M | 28.9 M |
Operating Expenses of other stocks in the Diagnostics research industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
58 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
77.2 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Agilent Technologies
A
|
1.99 B | $ 118.25 | -1.25 % | $ 35.9 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
726 M | - | - | $ 236 M |  China |
 |
Check-Cap Ltd.
CHEK
|
14.1 M | - | - | $ 9.42 M |  Israel |
 |
Aspira Women's Health
AWH
|
13.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
21.6 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
28.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Medpace Holdings
MEDP
|
118 M | $ 515.65 | -0.56 % | $ 14.9 B | USA |
 |
CareDx, Inc
CDNA
|
411 M | $ 22.42 | 27.6 % | $ 1.19 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
59.4 M | - | - | $ 562 M |  Britain |
 |
NeoGenomics
NEO
|
430 M | $ 8.16 | -5.99 % | $ 1.05 B | USA |
 |
Neogen Corporation
NEOG
|
1.48 B | $ 9.24 | -1.91 % | $ 2 B | USA |
|
Akumin
AKU
|
778 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Exact Sciences Corporation
EXAS
|
2.47 B | - | - | $ 19.8 B | USA |
 |
Enzo Biochem
ENZ
|
47.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Koninklijke Philips N.V.
PHG
|
7.12 B | $ 28.63 | -1.58 % | $ 20 B |  Niderland |
 |
Co-Diagnostics
CODX
|
50.6 M | $ 1.46 | 2.82 % | $ 1.94 M | USA |
 |
Castle Biosciences
CSTL
|
59.5 M | - | - | $ 684 M | USA |
 |
Senseonics Holdings
SENS
|
61.8 M | $ 6.77 | -1.88 % | $ 282 M | USA |
 |
Soleno Therapeutics
SLNO
|
181 M | $ 52.57 | - | $ 2.67 B | USA |
 |
Global Cord Blood Corporation
CO
|
451 M | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
134 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
5.91 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
983 M | - | 0.12 % | $ 80.1 M | China |
 |
Neuronetics
STIM
|
104 M | $ 1.4 | 0.72 % | $ 92.3 M | USA |
 |
Charles River Laboratories International
CRL
|
607 M | $ 176.94 | -2.0 % | $ 8.77 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
585 M | - | - | $ 10.7 B | USA |
 |
Thermo Fisher Scientific
TMO
|
7.15 B | $ 516.0 | -2.95 % | $ 195 B | USA |
 |
Danaher Corporation
DHR
|
6.71 B | $ 193.78 | -2.2 % | $ 138 B | USA |
 |
Interpace Biosciences
IDXG
|
20 M | $ 2.2 | - | $ 9.73 M | USA |
 |
Trinity Biotech plc
TRIB
|
28.3 M | $ 0.7 | -0.54 % | $ 61.9 M |  Irlanda |
 |
Heska Corporation
HSKA
|
131 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
24.1 M | - | -20.0 % | $ 1.06 M | USA |
 |
Twist Bioscience Corporation
TWST
|
116 M | $ 56.23 | -2.41 % | $ 3.36 B | USA |
 |
Illumina
ILMN
|
3.69 B | $ 132.72 | 0.35 % | $ 21.1 B | USA |
 |
Fulgent Genetics
FLGT
|
181 M | $ 16.13 | -0.25 % | $ 488 M | USA |
 |
Guardant Health
GH
|
226 M | $ 85.7 | 0.99 % | $ 10.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
821 M | - | - | $ 10.6 B | Niderland |
 |
Anixa Biosciences
ANIX
|
9.98 M | $ 2.83 | -3.41 % | $ 91.8 K | USA |
 |
Biomerica
BMRA
|
5.64 M | $ 2.2 | 4.27 % | $ 5.05 M | USA |
 |
Waters Corporation
WAT
|
687 M | $ 319.04 | -2.19 % | $ 19 B | USA |
 |
ICON Public Limited Company
ICLR
|
408 M | $ 115.58 | -0.79 % | $ 9.53 B | Irlanda |
 |
Laboratory Corporation of America Holdings
LH
|
1.87 B | $ 266.36 | -0.14 % | $ 22.2 B | USA |
 |
Motus GI Holdings
MOTS
|
18.6 M | - | -34.28 % | $ 263 K | Israel |
 |
Celcuity
CELC
|
172 M | - | - | $ 5.87 B | USA |
 |
Myriad Genetics
MYGN
|
964 M | $ 5.0 | -3.66 % | $ 463 M | USA |
 |
Lantheus Holdings
LNTH
|
123 M | $ 83.92 | -0.02 % | $ 5.66 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.46 B | $ 191.46 | 0.02 % | $ 21.3 B | USA |